Scarica l'app Stockscreener
0.00
0.00%
0.00
Precedente Chiudi:
$0.00
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
Capitalizzazione di mercato:
$N/A
Reddito:
$1.65M
Utile/perdita netta:
$-5.91M
Rapporto P/E:
0.00
EPS:
-0.1707
Flusso di cassa netto:
$-3.03M
1 W Prestazione:
+0.00%
1M Prestazione:
+0.00%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$0.00
Vitro Biopharma, Inc. Stock (VTRO) Company Profile
Nome
Vitro Biopharma, Inc.
Settore
Industria
Telefono
(720) 859-4120
Indirizzo
4621 TECHNOLOGY DRIVE, GOLDEN
Compare VTRO vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VTRO
Vitro Biopharma, Inc.
|
0.00 | 0 | 1.65M | -5.91M | -3.03M | -0.1707 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Vitro Biopharma, Inc. Borsa (VTRO) Ultime notizie
Best Biotech Stocks of 2026 and How to Invest in Them - The Motley Fool
Reviewing Rein Therapeutics (NASDAQ:RNTX) and Vitro Diagnostics (OTCMKTS:VODG) - Defense World
Financial Contrast: Imunon (NASDAQ:IMNN) vs. Vitro Diagnostics (OTCMKTS:VODG) - Defense World
What Stem Cell Clinics Do You Trust? - BioInformant
Vitro Biopharma Receives ISO 13485 Certification Supporting its Stem Cell Medical Tourism Initiative - ACCESS Newswire
Vitro Biopharma Retains Leading Health Care Executive as Acting Director of Regulatory Affairs & Director - ACCESS Newswire
10 cultured meat companies driving sustainable food in 2025 - Labiotech.eu
Vitro Biopharma's AlloRx Stem Cell TherapyFeatured in New York Times Article on Health Secretary Kennedy's, Vision for Expanding Access to Regenerative Medicine - ACCESS Newswire
Vitro Biopharma's AlloRx Stem Cell Therapy Featured in New York Times Article on Health Secretary Kennedy's Vision for Expanding Access to Regenerative Medicine - ACCESS Newswire
Vitro Biopharma Receives FDA Authorization to Conduct a Clinical Trial Using AlloRx Stem Cells(R) to Treat COVID-19 - ACCESS Newswire
Be Biopharma to Present at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting - CRISPR Medicine News
Dealmaking Quarterly Statistics, Q4 2024 - Citeline News & Insights
Akoya Biosciences Selects Argonaut Manufacturing Services as IVD Manufacturing Partner - Business Wire
In Vitro Diagnostics (IVD) Market Size to Surpass USD 157.56 Billion by 2034 - BioSpace
Swiss biotech going strong in 2024: 18 companies to put on your radar - Labiotech.eu
Dealmaking Quarterly Statistics, Q2 2022 - insights.citeline.com
Top 5 In-Vitro Diagnostics [IVD] Companies, Worldwide by 2024 - Fortune Business Insights
A biotech working on a new approach to IVF raises $33M in fresh funding - BioPharma Dive
New In Vitro Data Showing Matinas BioPharma’s LNC Platform - GlobeNewswire
GenScript Biotech Corporation Announces Self-Amplifying RNA Synthesis Service for Advanced Therapeutic Applications - BioSpace
FDA defends lab test rule, as critics fear industry upheaval - BioPharma Dive
ProteoMixture: A cell type deconvolution tool for bulk tissue proteomic data - ScienceDirect.com
Vitro Biopharma adds Crown Resorts legal, compliance chief to board - Compliance Week
SIRION Biotech - Pharmaceutical Technology
Vitro Biopharma Announces Thomas Ohrt New Chief Financial Officer - MarketScreener
Vitro Biopharma, Inc. Announces Chief Financial Officer Changes - marketscreener.com
Kirk Cousins travels to Caribbean for stem cell treatment - kare11.com
Tickers - Finansavisen
In Vitro Fertilization (IVF) Market Size & Share to Surpass $1296.47 Mn by 2030 | Vantage Market Research - Yahoo Finance
IPO Update: Vitro Biopharma Aims For $10 Million U.S. IPO (VTRO) - Seeking Alpha
VTRO IPO NewsStem cell biotech Vitro Biopharma sets terms for $10 million IPO - renaissancecapital.com
Global Stem Cells Market Research Report 2023: Implications - GlobeNewswire
Vitro Biopharma, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
GT Biopharma Poster Presentation and Mini Oral Session at - GlobeNewswire
Vitro Biopharma Names Chris Furman Chief Executive Officer - Yahoo Finance
Business of Biotechniques 2022 - BioTechniques
Regen BioPharma, Inc. Announces Signing of a Letter of Intent to Acquire an In vitro Diagnostics Start-Up Company Canary Oncoceutics, Inc. Which is Developing Functional Cancer Tests for Personalized Medicine - Stock Titan
Developing A Robust In Vitro Intestinal Model For Preclinical Candidate Screening Of GI Toxicity - Pharmaceutical Online
User - FinancialContent
Vitro Biopharma Receives FDA Authorization to Conduct a Clinical Trial Using AlloRx Stem Cells® to Treat COVID-19 - BioInformant
DVC Stem: Stem Cell Therapy Clinic in the Cayman Islands - BioInformant
In vitro glycoengineeringSuitability for BioPharma manufacturing - Labroots
Critically Ill COVID-19 Patient Successfully Treated with Vitro Biopharma’s AlloRx Stem Cells(R) - BioInformant
Vor Biopharma Raises $110M to Develop Engineered Hematopoietic Stem Cells - BioInformant
Vitro Bio-Pharma 2nd Quarter Ended April 30th 2020 Financial Results of Operations and Shareholder Letter - ACCESS Newswire
VODG), dba Vitro Biopharma, announced its 2nd quarter ended April 30 th 2019 financial results of operations. - SEC.gov
Fujifilm Acquiring Irvine Scientific, IS Japan for $800M, with Cell Culture Media Growth in MindGEN - GEN - Genetic Engineering and Biotechnology News
Global Stem Cell Technologies and Applications Market 2018-2018Visiongain Report - PR Newswire UK
Here Are the Top 10 In Vitro Diagnostic Companies - BioSpace
Merck KGaA debuts new fertility tech division - BioPharma Dive
Vitro Diagnostics (VODG) Stock Price, News & Analysis - MarketBeat
Vitro Biopharma, Inc. Azioni (VTRO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.24%
0.19%
Capitalizzazione:
|
Volume (24 ore):